The future of skin health and beauty in San Francisco

After 20 years of combined research, I founded Spartia Therapeutics to turn advances in RNA biology into a new class of precision oncology treatments. Spartia is founded on the belief that the next generation of cancer care will be driven by RNA-targeted interventions, opening previously undruggable pathways and reshaping how we treat complex diseases.

To accelerate this vision, I co-located Spartia with Quantum Dermatology, a next-generation Skin Cancer Institute in San Francisco, to create a fully integrated innovation hub where discovery, computation, and clinical care converge. This model enables us to connect quantum-informed drug design, molecular dynamics, and AI-driven diagnostics directly with real-time patient care.

At the clinical core of this platform is the 3D Intelligent Patient Room—a transformative environment that captures the patient as a dynamic, data-rich system. By integrating Vectra 360 3D imaging, AI-powered dermoscopy, and clinical reasoning platforms, we create a continuous, non-invasive layer of intelligence that enables early detection, longitudinal monitoring, and personalized intervention.

Together, Spartia and Quantum Dermatology are building a new paradigm: from reactive medicine to predictive, data-driven care—where diagnostics and therapeutics evolve together to anticipate and intercept disease.